Literature DB >> 16982780

In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.

Ellie J C Goldstein1, Diane M Citron, C Vreni Merriam, Yumi A Warren, Kerin L Tyrrell, Helen T Fernandez.   

Abstract

Against 443 aerobic and anaerobic bacteria isolated from diabetic foot infections, ceftobiprole MICs (microg/ml) at which 90% of the isolates tested were inhibited were as follows: methicillin-resistant Staphylococcus aureus, 1; methicillin-susceptible S. aureus and Staphylococcus lugdunensis, 0.5; Anaerococcus prevotii, 0.125; Finegoldia magna, 0.5; Peptoniphilus asaccharolyticus, 1; Peptostreptococcus anaerobius, 4; Escherichia coli and Enterobacter species, 0.125; Klebsiella species, 2; and Pseudomonas aeruginosa, 8.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16982780      PMCID： PMC1635191          DOI： 10.1128/AAC.00722-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria.

Authors:  Nicolas C Issa; Mark S Rouse; Kerryl E Piper; Walter R Wilson; James M Steckelberg; Robin Patel
Journal:  Diagn Microbiol Infect Dis       Date:  2004-01       Impact factor: 2.803

2.  Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates.

Authors:  Lalitagauri Deshpande; Paul R Rhomberg; Thomas R Fritsche; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.803

3.  Diabetic foot infections. Bacteriology and activity of 10 oral antimicrobial agents against bacteria isolated from consecutive cases.

Authors:  E J Goldstein; D M Citron; C A Nesbit
Journal:  Diabetes Care       Date:  1996-06       Impact factor: 19.112

4.  Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.

Authors:  Tatiana Bogdanovich; Lois M Ednie; Stuart Shapiro; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

5.  In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci.

Authors:  P Hebeisen; I Heinze-Krauss; P Angehrn; P Hohl; M G Page; R L Then
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials.

Authors:  M Wootton; K E Bowker; H A Holt; A P MacGowan
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

7.  In vitro activities of BAL9141, a novel broad-spectrum pyrrolidinone cephalosporin, against gram-negative nonfermenters.

Authors:  R Zbinden; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 8.  Foot infections in diabetic patients: the role of anaerobes.

Authors:  D N Gerding
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

9.  Patterns of foot examination in a diabetes clinic.

Authors:  T S Bailey; H M Yu; E J Rayfield
Journal:  Am J Med       Date:  1985-03       Impact factor: 4.965
  9 in total
  15 in total

1.  Recent Advances in the Rational Design and Optimization of Antibacterial Agents.

Authors:  Jesse A Jones; Kristopher G Virga; Giuseppe Gumina; Kirk E Hevener
Journal:  Medchemcomm       Date:  2016-07-07       Impact factor: 3.597

2.  Truncated Autoinducing Peptides as Antagonists of Staphylococcus lugdunensis Quorum Sensing.

Authors:  Christopher P Gordon; Shondra D Olson; Jessica L Lister; Jeffrey S Kavanaugh; Alexander R Horswill
Journal:  J Med Chem       Date:  2016-09-15       Impact factor: 7.446

3.  Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2011-02-22       Impact factor: 5.191

Review 4.  Methicillin-resistant Staphylococcus aureus in diabetic foot infections.

Authors:  Ioanna Eleftheriadou; Nicholas Tentolouris; Vasiliki Argiana; Edward Jude; Andrew J Boulton
Journal:  Drugs       Date:  2010-10-01       Impact factor: 9.546

5.  New insights in diabetic foot infection.

Authors:  Jean-Louis Richard; Albert Sotto; Jean-Philippe Lavigne
Journal:  World J Diabetes       Date:  2011-02-15

6.  Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates.

Authors:  Cesar A Arias; Kavindra V Singh; Diana Panesso; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

7.  Peptoniphilus asaccharolyticus-associated septic arthritis and osteomyelitis in a woman with osteoarthritis and diabetes mellitus.

Authors:  Rajanshu Verma; Shogofa Morrad; Jason J Wirtz
Journal:  BMJ Case Rep       Date:  2017-06-02

Review 8.  From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis.

Authors:  Kristi L Frank; José Luis Del Pozo; Robin Patel
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 9.  Bone and joint infections due to anaerobic bacteria: an analysis of 61 cases and review of the literature.

Authors:  G Walter; M Vernier; P O Pinelli; M Million; M Coulange; P Seng; A Stein
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-02-28       Impact factor: 3.267

10.  Management of diabetic foot infections in an era of increasing microbial resistance.

Authors:  Sandra Bliss Nelson
Journal:  Curr Infect Dis Rep       Date:  2009-09       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.